Q&M buys Covid-19 test kits, related business
A WHOLLY-OWNED subsidiary of Q&M Dental Group on Friday completed its acquisition of Covid-19 test kits and related business from biotech company Acumen Research Laboratories (ARL), Q&M said in a bourse filing late on Sunday.
The subsidiary, Acumen Diagnostics, is a joint venture between Q&M and ARL founder Ong Siew Hwa. Q&M in April agreed to invest S$3 million in cash from internal funds into Acumen Diagnostics to build a new Covid-19 testing business.
Q&M on Sunday said that following internal review and due diligence, Acumen Diagnostics had agreed to pay ARL an additional S$250,000 in cash, subject to certain performance conditions having been met.
This amount will be paid from Q&M's S$3 million injection into Acumen Diagnostics, the mainboard-listed company said.
As part of the joint venture agreement announced in April, Acumen Diagnostics was to issue new shares to Dr Ong, Dr Ong's sister-in-law Amy Zeng, and Acumen Holdings, such that they will each hold 30.7 per cent, 5 per cent and 13.3 per cent of Acumen Diagnostics, respectively.
Ms Zeng has been helping Dr Ong with sales at ARL, while Acumen Holdings is a private investment holding company. Dr Ong, Ms Zeng and Acumen Holdings will work with Q&M to develop Acumen Diagnostics' business further, Q&M said then.
A NEWSLETTER FOR YOU
SGSME
Get updates on Singapore's SME community, along with profiles, news and tips.
Following the completion of the share subscriptions on Friday, Q&M's shareholding in Acumen Diagnostics is now 51 per cent, it said.
Q&M shares ended Friday at 44 Singapore cents, down 0.5 cent or 1.1 per cent.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Honda to spend US$11 billion on EV strategy in Canada
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
Mapletree Industrial Trust Q4 DPU rises 0.9% to S$0.0336
Nasdaq’s profit falls as shaky economy keeps IPO revival elusive
iFast Q1 net profit surges on ePension unit performance
Suntec Reit Q1 DPU down 13% to S$0.01511 in absence of capital distribution